PAVmed Inc. (PAVM) 株式分析

企業概要

PAVmed Inc. is an entity engaged in the acquisition, development, and commercialization of novel medical products designed to address unmet clinical needs within the United States market. The company operates specifically within the Healthcare sector and the Medical Devices industry, focusing on the creation of specialized surgical instruments such as CarpX, a patented disposable device for treating carpal tunnel syndrome. In terms of scale, the enterprise holds a market capitalization of $62.14M, reports annual revenue (TTM) of $71,000, and employs a workforce of 41 individuals. These valuation and revenue figures indicate that PAVmed Inc. is a micro-cap company with very limited commercial traction relative to its operational scope, suggesting a high-risk profile typical of early-stage biotechnology or medical device firms that are still in the process of product rollout or market penetration rather than mature revenue generation.

財務健全性

The financial performance metrics for PAVmed Inc. reveal significant challenges in converting top-line sales into profitability, with revenue (TTM) standing at $71,000 while net income (TTM) registers at a loss of $-3,774,000. The substantial gap between the negligible revenue and the multi-million dollar net loss highlights a cost structure dominated by high operating expenses, likely associated with research and development costs or administrative overheads that exceed current sales volumes. Additionally, the company reports an EBITDA of $-21,701,000 and a free cash flow of $-13,997,875, indicating a severe lack of financial flexibility and an ongoing burn rate that depletes available capital reserves. The margin analysis presents a complex picture where the gross margin is listed at -207.0%, the operating margin at -13082.7%, and the profit margin at 564.8%; these anomalous figures, particularly the negative gross and operating margins, suggest that the company's cost of goods sold exceeds its revenue significantly, while the positive profit margin appears to be an accounting artifact resulting from the massive net loss relative to the tiny revenue base. On the balance sheet, the company holds $1.95M in cash but carries $13.35M in debt, resulting in a debt-to-equity ratio of 59.86, which signifies a highly leveraged position that increases financial risk during periods of restricted access to capital markets. Liquidity is critically constrained, as evidenced by a current ratio of 0.17, meaning the company possesses less than one-fifth of the current assets necessary to cover its short-term liabilities without raising additional funds. Furthermore, the return on equity is -32.3% and the return on assets is -39.2%, metrics that collectively indicate that management has been ineffective at generating positive returns on shareholder capital or total assets over the trailing twelve months.

バリュエーション評価

Valuation multiples for PAVmed Inc. present a mixed picture due to the lack of earnings, with the P/E Ratio (TTM) listed as N/A and the forward P/E at -0.58, implying that traditional earnings-based valuation models are currently inapplicable until the company achieves profitability. The price-to-book ratio stands at 0.98, suggesting that the market values the company's equity at slightly less than its net asset value, though this metric can be misleading for firms with significant intangible assets or negative book value components. Alternative valuation metrics such as the price-to-sales ratio of 875.25 and the EV/EBITDA of -3.99 further illustrate the difficulty in assigning a reasonable multiple to a company with negative earnings and minimal sales. Regarding trading range, the stock has a 52-week high of $28.44 and a 52-week low of $6.00, meaning the current price sits somewhere within this wide volatility band, reflecting the uncertainty surrounding the company's future commercial success. The beta value is 0.81, which indicates that the stock's price volatility is slightly lower than the broader market average, suggesting that while the stock is less sensitive to general market swings, it remains subject to significant idiosyncratic risk given its micro-cap status and negative financials.

Growth & Income

The growth profile of PAVmed Inc. shows a revenue growth (YoY) of 420.0%, while earnings growth (YoY) is N/A due to the company not yet generating positive earnings. This disparity implies that the recent revenue increase is being heavily offset by escalating costs, preventing any realization of earnings growth despite the massive top-line expansion. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically reinvested into operations or retained to service debt, though current losses limit the ability to fund growth through internal cash generation. Overall, the company exhibits a growth-oriented financial structure with zero income distribution, relying entirely on external financing or remaining cash reserves to fund its ambitious product development and commercialization efforts in the medical device sector.